Two Scientific Remimazolam Presentations Are Accepted for ASA and ACG Meeting in October 2014 - Seite 3

25% of the patients in the Midazolam group received Propofol as sedative rescue medication compared to 5 % in the combined Remimazolam groups who received either Propofol or Midazolam. This study from 2010 was the third showing a clinically relevant improvement in the course of sedation in comparison to Midazolam.

"We are proud that distinguished scientific organizations like ASA and ACG accepted scientific Remimazolam presentations. This shows that the current product profile attracts increasing attention and underscores the medical need both in conscious sedation and general anesthesia. The presentation of Remimazolam during scientific conferences and congresses is part of the international scientific dialogue about Remimazolam. Furthermore this will initiate our pre-marketing activities that we conduct to accompany the Phase III program both in the US and Europe," comments Dr. Wolfgang Söhngen, CEO at PAION.

About Remimazolam
Remimazolam is an innovative short-acting general anaesthetic/sedative. Due to its short duration of action and good controllability, it has a preferable efficacy and safety profile relative to other currently marketed anaesthesia compounds. The rapid offset of Remimazolam's effect is due to its metabolism by tissue esterase enzymes that are widely distributed throughout the body. Remimazolam has potential in three indications:

• Procedural sedation
• General anaesthesia
• ICU sedation

Remimazolam is available for licensing outside Japan, China, Russia (CIS) Turkey, South Korea and Canada, where the compound is partnered with, Ono Pharmaceutical, Yichang Humanwell, R-Pharm, Hana Pharm and Pendopharm.

About PAION
PAION AG is a publicly-listed Specialty Pharma Company headquartered in Aachen, Germany with a second site in Cambridge, UK. The company has a track record in developing hospital-based treatments for which there is substantial unmet medical need. PAION's strategy is to extend its business model from a pure development company to a specialty pharmaceutical company with a focus on anaesthesia products. Remimazolam is intended to be the basis for its future marketing activities.

Disclaimer:

This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG's management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments.

PAION Contact
Ralf Penner
Director Investor Relations / Public Relations
PAION AG
Martinstrasse 10-12
52062 Aachen - Germany
Phone: [phone]
E-mail: [e-mail]
www.paion.com